Celgene wins Chinese regulatory OK for Revlimid

Mon Feb 11, 2013 7:35pm IST

Related Topics

Stocks

   
Inside the Peshawar school

Inside the Peshawar school

The aftermath inside the Pakistan school where at least 132 students and nine staff members were killed by Taliban gunmen.  Pictures 

(Reuters) - Celgene Corp on Monday said its drug Revlimid won full regulatory approval in China for patients with relapsed or refractory multiple myeloma, a type of cancer that starts in the plasma cells in the bone marrow.

Multiple myeloma is the second most commonly diagnosed blood cancer. There are an estimated 750,000 people with the disease worldwide, according to the International Myeloma Foundation.

Celgene said it expects the drug to be available to Chinese patients late in the second quarter of 2013.

In addition, the biotechnology company said Revlimid, or lenalidomide, was granted priority review by the U.S. Food and Drug Administration as a treatment for patients with relapsed or refractory mantle cell lymphoma.

Revlimid is approved in combination with dexamethasone for the treatment of patients with multiple myeloma, who have received at least one prior therapy, in almost 70 countries, including the Americas and Europe.

It is also approved in the United States, Canada, Switzerland, Australia, New Zealand and several Latin American countries, as well as Malaysia and Israel, for transfusion-dependent anemia.

(Reporting By Debra Sherman; Editing by Gerald E. McCormick)

FILED UNDER:

Health

REUTERS SHOWCASE

26/11 Accused

26/11 Accused

Pakistan to appeal bail for Mumbai attack "mastermind".  Full Article 

Android For cars

Android For cars

Exclusive: Google aiming to go straight into car with next Android – sources.  Full Article 

Mass Stabbing

Mass Stabbing

Eight children killed in Australia in reported mass stabbing.  Full Article 

In Distress

In Distress

Former SpiceJet owner leading rescue plan: reports.  Full Article 

PM's Moves

PM's Moves

Modi moves in to speed up $300 billion stuck projects.  Full Article 

Losing Popularity

Losing Popularity

Dalai Lama's star waning in the West, China official says.  Full Article 

Tis' The Season

Tis' The Season

Stars around the world wish you Happy Holidays.  Video 

Cyber Warfare

Cyber Warfare

For N.Korea's cyber army, long-term target may be telecoms, utility grids.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device   Full Coverage